Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) posted EBT Margin of 6003.3% for Q4 2024, up 134.35% on a QoQ basis from 17476.92% in Q3 2024, and up 599733.0% year-over-year from N/an in Q1 2024.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals has reported EBT Margin for 4 years, with the latest figure at 6003.3% in Q4 2024.
- On a quarterly basis, EBT Margin rose 599733.0% year-over-year to 6003.3% in Q4 2024; TTM through Sep 2025 was 23571.86%, a 2370155.0% increase from a year earlier, with the FY2024 full-year figure at 345.69%, down 35995.0% from the prior year.
- EBT Margin was 6003.3% for Q4 2024 at Amylyx Pharmaceuticals, up from 17476.92% in the prior quarter.
- The five-year high for EBT Margin was 6003.3% in Q4 2024, with the low at 17476.92% in Q3 2024.
- Average EBT Margin over 4 years is 3872.26%, with a median of 133.74% recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: EBT Margin jumped 1563950 bps in 2023, then slumped 1749875 bps in 2024.
- Over 4 years, EBT Margin stood at 8120.0% in 2021, then surged by 98 bps to 197.52% in 2022, then soared by 103 bps to 5.97% in 2023, then soared by 100433 bps to 6003.3% in 2024.
- The last three EBT Margin figures came in at 6003.3% (Q4 2024), 17476.92% (Q3 2024), and 7106.55% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -20,427.46% |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 6,003.30% |
| Sep 30, 2024 | -17,476.92% |
| Jun 30, 2024 | -7,106.55% |
| Mar 31, 2024 | -133.74% |
| Dec 31, 2023 | 5.97% |
| Sep 30, 2023 | 21.82% |
| Jun 30, 2023 | 24.44% |
| Mar 31, 2023 | 1.96% |
| Dec 31, 2022 | -197.52% |
| Sep 30, 2022 | -15,617.68% |
| Sep 30, 2021 | -8,120.00% |